Department of Nutrition and Institute for Global Nutrition, University of California, Davis, CA 95616, USA.
Department of Medicine, University of Missouri School of Medicine, Columbia, MO 65212, USA.
Nutrients. 2023 May 31;15(11):2590. doi: 10.3390/nu15112590.
To assess (a) the impact of daily preventive zinc tablets (7 mg; PZ), zinc-containing multiple micronutrient powder (10 mg zinc, and 13 other micronutrients; MNP) or placebo, delivered for 9 months, on Insulin-like Growth Factor 1 (IGF1) and IGF Binding Protein 3 (IGFBP3) among Laotian children 6-23 months, and (b) whether the effects of PZ and MNP on length-for-age z-scores (LAZ) and weight-for-age z-scores (WAZ) are modified by baseline IGF1 and IGFBP3.
A double-blind, placebo-controlled trial (N = 419).
Plasma IGF1 and IGFBP3 concentrations at baseline and 36 weeks were analyzed by automated chemiluminescent assay. Anthropometry was assessed at baseline, at 18 and 36 weeks. Intervention effects were estimated using ANCOVA.
At 36 weeks, geometric mean IGF1 (~39.0-39.2 ng/mL; = 0.99) and IGFBP3 (2038-2076 ng/mL; = 0.83) did not differ by group. At 18 weeks (but not at 36 weeks), LAZ in the PZ group (-1.45) was higher than the MNP (-1.70) and control (-1.55) groups ( = 0.01) among children in the highest baseline IGF1 tertile ( for interaction = 0.006). At 36 weeks (but not at 18 weeks), WAZ in the PZ group (-1.55) was significantly higher than the MNP (-1.75) and control (-1.65) groups ( = 0.03), among children in the lowest baseline IGFBP3 tertile ( for interactions = 0.06).
Although IGF1 and IGFBP3 did not respond to PZ and MNP, baseline IGF1 and IGFBP3 significantly modified the impact of PZ on linear and ponderal growth, suggesting that IGF1 bioavailability may drive catch-up growth in zinc-supplemented children.
评估(a)每日预防性锌片(7 毫克;PZ)、含锌多种微量营养素粉(10 毫克锌和 13 种其他微量营养素;MNP)或安慰剂,连续服用 9 个月,对 6-23 个月老挝儿童胰岛素样生长因子 1(IGF1)和 IGF 结合蛋白 3(IGFBP3)的影响,以及(b)PZ 和 MNP 对年龄别身长 z 评分(LAZ)和年龄别体重 z 评分(WAZ)的影响是否受基线 IGF1 和 IGFBP3 的影响。
一项双盲、安慰剂对照试验(N = 419)。
采用自动化化学发光法分析基线和 36 周时的血浆 IGF1 和 IGFBP3 浓度。基线、18 周和 36 周时进行人体测量。使用方差分析(ANCOVA)估计干预效果。
36 周时,IGF1(~39.0-39.2ng/mL; = 0.99)和 IGFBP3(2038-2076ng/mL; = 0.83)的几何均数在各组间无差异。18 周时(而非 36 周时),PZ 组(-1.45)的 LAZ 高于 MNP 组(-1.70)和对照组(-1.55),且在 IGF1 基线最高三分位的儿童中差异有统计学意义( = 0.01;交互作用 = 0.006)。36 周时,PZ 组(-1.55)的 WAZ 明显高于 MNP 组(-1.75)和对照组(-1.65),且在 IGFBP3 基线最低三分位的儿童中差异有统计学意义( = 0.03;交互作用 = 0.06)。
尽管 IGF1 和 IGFBP3 对 PZ 和 MNP 无反应,但基线 IGF1 和 IGFBP3 显著改变了 PZ 对线性和体重增长的影响,提示 IGF1 生物利用度可能是补锌儿童追赶生长的驱动因素。